【レポートの概要（一部）】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
• Understanding the disease
• Etiology
• Signs and symptoms
• Diagnosis
• Management
• Economic burden
• Epidemiology
PART 06: Pipeline portfolio
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type of disease
• RA
• MS
• PsA
• IBD
• AS
• SLE
• Global RA drugs market
• Clinical trials for RA
• Global MS drugs market
• Global PsA drugs market
• Global IBD drugs market
• Global AS drugs market
• Global SLE drugs market
PART 09: Market segmentation by mechanism of action
• TNF inhibitors
• IL-1 blockers
• COX inhibitors
• PDE4 inhibitors
• Others
PART 10: Market segmentation by drug class
• DMARDs
• NSAIDs
• Corticosteroids
• Analgesics
• Immunosuppressants
• Others
PART 11: Market segmentation by type of molecule
• Biologics
• Small molecules
PART 12: Market segmentation by ROA
• Oral
• Parenteral
• Topical
PART 13: Market segmentation by dosage form
• Solid
• Liquid
• Semi-solid
PART 14: Geographical segmentation
• Autoimmune diseases drugs market in the Americas
• Autoimmune diseases drugs market in US
• Autoimmune diseases drugs market in EMEA
• Autoimmune diseases drugs market in APAC
• Autoimmune diseases drugs market in Japan
• Autoimmune diseases drugs market in China
PART 15: Market drivers
• Rising prevalence of autoimmune diseases
• Growing older population
• Dominance of biologics
• Unmet medical needs
• Promising pipeline
PART 16: Impact of drivers
PART 17: Market challenges
• Increasing cost of biologics
• Loss of patent exclusivity of branded therapies
• Complex nature of autoimmune diseases
• Preference for CAMs
• Adverse effects
PART 18: Impact of drivers and challenges
PART 19: Market trends
• Emergence of biosimilars
• Patient assistance programs
• Increase in public awareness programs
• Strategic alliances
• Popularity of off-label and traditional treatment options
PART 20: Vendor landscape
• Competitive scenario
• Market analysis 2015
• AbbVie
• Johnson & Johnson
• Biogen
• Amgen
• Pfizer
• F. Hoffmann-La Roche
• Other prominent vendors
PART 21: Appendix
• List of abbreviations
PART 22: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Etiology of autoimmune diseases
Exhibit 03: Signs and symptoms of autoimmune diseases
Exhibit 04: Diagnostic methods for autoimmune diseases
Exhibit 05: Non-pharmacological therapies used for autoimmune diseases
Exhibit 06: Pharmacotherapy therapies used for autoimmune diseases
Exhibit 07: Top drugs for autoimmune diseases
Exhibit 08: Average annual treatment costs of RA in US and Europe 2014 ($ billions)
Exhibit 09: Average annual treatment costs of MS across countries 2014 ($ billions)
Exhibit 10: Average annual treatment costs of PsA across countries 2014 ($ billions)
Exhibit 11: Prevalence and incidence of SLE
Exhibit 12: Pipeline molecules for RA
Exhibit 13: Pipeline molecules for MS
Exhibit 14: Pipeline molecules for PsA
Exhibit 15: Pipeline molecules for CD
Exhibit 16: Pipeline molecules for UC
Exhibit 17: Pipeline molecules for SLE
Exhibit 18: Global autoimmune diseases drugs market 2015-2020 ($ billions)
Exhibit 19: Five forces analysis
Exhibit 20: Global autoimmune diseases drugs market segmentation by type of disease
Exhibit 21: Global autoimmune diseases drugs market by type of disease 2015
Exhibit 22: Global autoimmune diseases drugs market: YoY revenue and growth based on autoimmune diseases 2015-2020
Exhibit 23: Global RA drugs market 2015-2020 ($ billions)
Exhibit 24: Global RA drugs market by drug class 2015
Exhibit 25: Top-vendor offerings for global RA drugs market
Exhibit 26: RA clinical trial by Phase 2015
Exhibit 27: RA clinical trial by status 2015
Exhibit 28: Drivers and challenges of global RA drugs market
Exhibit 29: Global MS drugs market 2015-2020 ($ billions)
Exhibit 30: Global MS drugs market by molecule type 2015
Exhibit 31: Top-vendor offerings for global MS drugs market
Exhibit 32: Drivers and challenges of global MS drugs market
Exhibit 33: Global PsA drugs market 2015-2020 ($ billions)
Exhibit 34: Global PsA drugs market segmentation by MOA 2015
Exhibit 35: Top-vendor offerings for global PsA drugs market
Exhibit 36: Drivers and challenges of global PsA drugs market
Exhibit 37: Global IBD drugs market 2015-2020 ($ billions)
Exhibit 38: Global IBD drugs market by type of disease 2015
Exhibit 39: Global IBD drugs market by drug class 2015
Exhibit 40: Top-vendor offerings for global IBD drugs market
Exhibit 41: Drivers and challenges of global IBD drugs market
Exhibit 42: Global AS drugs market 2015-2020 ($ billions)
Exhibit 43: Global AS drugs market by MOA 2015
Exhibit 44: Top-vendor offerings for global AS drugs market
Exhibit 45: Drivers and challenges of global AS drugs market
Exhibit 46: Global SLE drugs market 2015-2020 ($ billions)
Exhibit 47: Drivers and challenges of global SLE drugs market
Exhibit 48: Global autoimmune diseases drugs market segmentation by MOA
Exhibit 49: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 50: Global autoimmune diseases drugs market share by MOA 2015
Exhibit 51: Global autoimmune diseases drugs market segmentation by drug class
Exhibit 52: Examples of non-biologic DMARDs and biologic DMARDs for autoimmune diseases
Exhibit 53: NSAIDs used to treat autoimmune diseases
Exhibit 54: Global autoimmune diseases drugs market by drug class 2015
Exhibit 55: Global autoimmune diseases drugs market segmentation by type of molecule
Exhibit 56: Global autoimmune diseases biologics market 2015-2020 ($ billions)
Exhibit 57: Global autoimmune diseases small molecules market 2015-2020 ($ billions)
Exhibit 58: Global autoimmune diseases drugs market by type of molecules 2015
Exhibit 59: Global autoimmune diseases drugs market segmentation by ROA
Exhibit 60: Global autoimmune diseases drugs market segmentation by ROA 2015
Exhibit 61: Global autoimmune diseases drugs market segmentation by dosage form
Exhibit 62: Global autoimmune disease drugs market segmentation by dosage form 2015
Exhibit 63: Global autoimmune diseases drugs market segmentation by geography 2015
Exhibit 64: Global autoimmune diseases drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 65: Autoimmune diseases drugs market in the Americas 2015-2020 ($ billions)
Exhibit 66: Autoimmune diseases drugs market in America by country 2015
Exhibit 67: Autoimmune diseases drugs market in US 2015-2020 ($ billions)
Exhibit 68: Drivers and challenges for autoimmune diseases drugs market in the US
Exhibit 69: Autoimmune diseases drugs market in EMEA 2015-2020 ($ billions)
Exhibit 70: Autoimmune diseases drugs market in APAC 2015-2020 ($ billions)
Exhibit 71: Autoimmune diseases drugs market in Japan 2015-2020 ($ billions)
Exhibit 72: Drivers and challenges for autoimmune diseases drugs market in Japan
Exhibit 73: Autoimmune diseases drugs market in China 2015-2020 ($ billions)
Exhibit 74: Global autoimmune diseases drugs market YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 75: Population aged 60 years and over ($ millions)
Exhibit 76: Biologics approval timeline by US FDA
Exhibit 77: Some pipeline molecules under phases of development for autoimmune diseases
Exhibit 78: Impact of drivers
Exhibit 79: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
Exhibit 80: Approval and patent expiries of top selling biologics
Exhibit 81: CAM therapies for autoimmune diseases
Exhibit 82: Usage of CAM therapies among individuals in US 2014
Exhibit 83: Adverse effects associated with autoimmune disease therapies
Exhibit 84: Impact of drivers and challenges
Exhibit 85: Patient assistance programs for autoimmune diseases drugs
Exhibit 86: Revenue share of major companies for autoimmune diseases 2015
Exhibit 87: YoY Sales comparison of top drugs 2013-2015 ($ billions)
Exhibit 88: AbbVie: Product segmentation by revenue 20150
Exhibit 89: AbbVie: YoY growth rate and revenue of HUMIRA 2013-2015 ($ billions)
Exhibit 90: AbbVie: YoY growth rate and revenue of HUMIRA in US 2013-2015 ($ billions)
Exhibit 91: AbbVie: YoY growth rate and revenue of HUMIRA in ROW 2013-2015 ($ billions)
Exhibit 92: Sales of HUMIRA in major markets
Exhibit 93: AbbVie: Key takeaways
Exhibit 94: Johnson & Johnson: Segmentation of key autoimmune diseases drugs 2014
Exhibit 95: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2014 ($ billions)
Exhibit 96: Johnson & Johnson: YoY growth rate and revenue of Remicade in US 2013-2015 ($ billions)
Exhibit 97: Johnson & Johnson: YoY growth rate and revenue of Remicade in ROW 2013-2015 ($ billions)
Exhibit 98: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 99: Johnson & Johnson: YoY growth rate and revenue of Stelara in US 2013-2015 ($ billions)
Exhibit 100: Johnson & Johnson: YoY growth rate and revenue of Stelara in ROW 2013-2015 ($ millions)
Exhibit 101: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 102: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in US 2013-2015 ($ millions)
Exhibit 103: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in ROW 2013-2015 ($ millions)
Exhibit 104: Johnson & Johnson: Key takeaways
Exhibit 105: Biogen: Product segmentation of key autoimmune diseases drugs by revenue 2015
Exhibit 106: Top selling autoimmune diseases drugs
Exhibit 107: Biogen: YoY growth rate and revenue of Tecfidera 2013-2015 ($ billions)
Exhibit 108: Biogen: YoY growth rate and revenue of Avonex 2013-2015 ($ billions)
Exhibit 109: Biogen: YoY growth rate and revenue of Tysabri 2013-2015 ($ billions)
Exhibit 110: Biogen: YoY revenue of Plegridy 2014-2015 ($ millions)
Exhibit 111: Biogen: YoY growth rate and revenue of Fampyra 2013-2015 ($ millions)
Exhibit 112: Biogen: Key takeaways
Exhibit 113: Amgen: YoY growth rate and revenue of Enbrel in US and Canada 2013-2015 ($ billions)
Exhibit 114: Amgen: YoY growth rate and revenue of Enbrel in US 2013-2015 ($ billions)
Exhibit 115: Amgen: YoY growth rate and revenue of Enbrel in Canada 2013-2015 ($ millions)
Exhibit 116: Amgen: Key takeaways
Exhibit 117: Pfizer: Autoimmune diseases drugs product segmentation by revenue 2014
Exhibit 118: Top selling autoimmune diseases drugs
Exhibit 119: Pfizer: YoY growth rate and revenue of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 120: Pfizer: YoY growth rate and revenue of Celebrex 2013-2015 ($ billions)
Exhibit 121: Pfizer: YoY growth rate and revenue of Xeljanz 2012-2014 ($ millions)
Exhibit 122: Pfizer: Key takeaways
Exhibit 123: Top selling autoimmune diseases drugs
Exhibit 124: F. Hoffmann-La Roche: YoY growth rate and revenue of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 125: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 126: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 127: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)
Exhibit 128: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 129: F. Hoffmann-La Roche: Key takeaways
【レポート販売概要】
■ タイトル：自己免疫疾患用薬の世界市場2016-2020■ 英文：Global Autoimmune Drugs Market 2016-2020
■ 発行日：2016年3月18日
■ 調査会社：Technavio
■ 商品コード：IRTNTR9055
■ 調査対象地域：グローバル
- 溶接用ガス/シールドガスの世界市場：酸素、水素、二酸化炭素MarketsandMarkets projects that the welding gas/shielding gas market will grow from USD 7.17 Billion in 2015 to USD 9.46 Billion by 2020 at a CAGR of 5.70%. The market for welding gas/shieling gas is growing, due to increasing applications of welding gas/shielding gas in the construction sector, growing aerospace industry, and rising demand for metal manufacturing & fabrication. Growing demand fro …
- 新生児スクリーニングの世界市場2015-2022According to Stratistics MRC, the newborn screening market is estimated at $540.4 million in 2015 and is projected to reach $1,240.2 million by 2022 growing at a CAGR of 12.6% from 2015 to 2022. Rising awareness and demand for newborn screening in developed nations, presence of federal bodies for organizing awareness programmes, rising paranoia of parents and government initiatives are some of the …
- クラウド式ITセキュリティサービスの世界市場2016-2020About the IT security as a service market The global IT security as a service market is growing steadily as cloud services remain the most promising market over the decade. Organizations can reduce risks by virtualizing applications and users, and integrating data leak protection functions into a secure cloud-hosted environment. This enables users to experience an improved traditional environment, …
- 高等教育の世界市場2019-2023102 pages, November 2018 About this market The rise in the adoption of advanced technologies to help the market grow during the forecast period. The adaptation to the rapid changes in higher education requires the tracking and understanding of the domestic and international shifts in needs. Many of the developed countries in the world, such as the US, the UK, and Japan, are early adopters of advan …
- リザーバー（油層・ガス層）解析サービスの世界市場This report provides analysis of reservoir analysis by type of services, such as reservoir simulation & geo-modeling, data acquisition & monitoring and reservoir sampling services that is used in onshore and offshore applications. The service segment includes market value as per the region that includes regions such as North America, South America, Europe, Asia-Pacific, the Middle East, and Africa …
- 通信事業者による決済及びバンキングの世界市場Global Mobile Operators: Strategies in Payments and Banking is a report and interactive PartnerBASE dataset that provides a detailed worldwide overview of the fast-growing involvement of mobile operator brands and groups across payment and banking services. For 286 brands spread across 92 countries, it outlines their activity and strategic partnerships for the following payment and banking product …
- 化学品物流の世界市場2015-2019About chemical logistics Logistics deals with the procurement, planning, and implementation of activities in the forward and reverse logistics chain of an organization. The chemical industry uses logistics for the complete management of the way resources are acquired, stored, and moved to different end-user locations. The use of logistics helps the chemical industry to have a continual supply of h …
- 北米の呼吸装置市場North America Respiratory Devices Market Outlook to 2021 Summary GlobalData’s new report, "North America Respiratory Devices Market Outlook to 2021", provides key market data on the North America Respiratory Devices market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Humidifiers, Oxygen Concentrators, Vent …
- 自動車タイミングベルトの世界市場2015-2019About timing belts Timing belts are one of the most critical components in an internal combustion engine (ICE) as it operates and controls the number of revolutions of the camshaft, which defines the power generated by the engine. As timing belts are placed close to the engine cylinder where the fuel air mixture combusts, it is exposed to a significant amount of heat. A major reason for timing bel …
- 繊維染料の世界市場予測（～2024年）The textile dyes market is projected to register a CAGR of 5.9%, in terms of value, between 2019 and 2024.The textile dyes market is projected to grow from USD 8.2 billion in 2019 to USD 10.9 billion by 2024, at a CAGR of 5.9%, between 2019 and 2024. APAC is the largest consumer of textile dyes. Low-cost of manufacturing in APAC countries and high demand for textile dyes in the region are driving …
- 世界の コーディングおよびマーキング市場動向（2014-2018）TechNavio's analysts forecast the Global Coding and Marking market to grow at a CAGR of 4.68 percent over the period 2014-2018. One of the key factors contributing to this market growth is the increasing need for product identification and brand protection. The Global Coding and Marking market has also been witnessing the increasing competition between laser and TIJ techniques. However, the issues …
- US Hospital Tumor Marker Testing Market 2014This new report from Venture Planning Group contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital tumor market testing market, including: Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics a …
- 世界の農業機器市場：耕うん機具、植栽機、施肥用器具などThe practice of agriculture around the world showed a significant change owing to the developments made in farm equipment industry. Mechanization in agriculture increasingly proved important and played a key role in agricultural production globally. The inclusion of mechanization not only influenced and reduced the workload, but changed the characteristics of labor in agricultural practices. Agric …
- 世界のクロマトグラフィー・アクセサリ及び消耗品市場動向と予測The global chromatography accessories and consumables market is a technology-driven market where technologies as well as their adoption by end users witness a rapid change. This market is expected to grow at a CAGR of 5.7% from 2013 to 2018, to reach $3.5 billion by 2018. In this report, the global chromatography accessories and consumables market is segmented across many levels, namely, market by …
- 世界の紙ストロー市場：材料種類別（バージンペーパー、再生紙）、製品種類別（印刷、非印刷）、ストロー長さ別、ストロー直径別、エンドユーズ用途別（食品サービス、施設、家庭）、地域別Increased demand for paper straws for various end-use applications and rise in government reforms & campaigns to ban plastics are projected to drive the overall growth of the paper straw market across the globe from 2019 to 2024. The paper straw market is projected to grow from USD 585 million in 2019 to USD 1,687 million by 2024, recording a CAGR of 23.6% during the forecast period. The growing c …
